The release of added context on the benefit-risk profile of CAR-T therapies underscores how safety is moving from the periphery into the category’s forefront.
As CAR-Ts go from candidates to brands, what’s the marketing strategy?
Biogen, UCB reportedly showing interest in Acorda acquisition; Kite Pharma and Pfizer to develop combo lymphoma therapy; hospitals to form generics nonprofit
Five things for pharma marketers to know: Thursday, December 21, 2017
BI to pay $13.5 million for misleading marketing; ICER: CAR-T therapies more cost-effective than chemotherapy; FDA approves Roche’s breast cancer combo therapy
Five things for pharma marketers to know: Tuesday, October 31, 2017
Pfizer Q3 revenue driven by Prevnar sales; President Trump’s opioid panel presents draft to combat crisis; Novartis seeks FDA approval for CAR-T therapy Kymriah
Five things for pharma marketers to know: Thursday, October 19, 2017
600 patients are eligible for CAR-T therapy; the FDA halts Keytruda combo study for multiple myeloma; the regulator delays decision on Herceptin biosimilar
Novartis’ CAR-T therapy, now approved, faces questions about price and side effects